Posters

Treatment of non infectious corneal ulcers using PRGF and RGTA matrix

Poster Details

First Author: E.Uribe Badillo PERU

Co Author(s):    R. Sanchez   J. Merayo                 

Abstract Details

Purpose:

To provide data about efficacy and safety of Plasma Rich in Growth Factors (PRGF) associated with tissue regenerating agent (RGTA) drops in treatment of non infected corneal ulcers

Setting:

Fernandez Vega University Institute - Eye Surface Unit (IUFV) Oviedo-Spain

Methods:

This retrospective study included patients of IUFV (Fernández-Vega University Institute) between 2010 and 2019, with non infected corneal ulcer and no response to standard treatments (at least 6 months). The treatment given was RGTA (1 drop every two days), if ulcer closure is not achieved, the PRGF eye drops treatment was added (4 times / day). Was evaluate the time to reach the ulcer closure; the Best Corrected Visual Acuity (BCVA), intraocular pressure (IOP), Visual Analog Scale (VAS, in frequency and severity of symptoms), and OSDI (Ocular Surface Disease Index) were also evaluated. The adverse events also were reported.

Results:

Seventy-four patients (79 eyes) were included, forty-six eyes (62.2%) were women and the age was 56.8 ± 17.3 years. The most frequent corneal ulcer was the neurotrophic one (n = 27, 34.2%), mainly due to herpes virus (n = 15, 19.0%). The treatment time with PRGF eye drops associated with RGTA matrix was 4.2 ± 2.2 (1.5 -9.0) months, the follow-up was 44.9 ± 31.5 months. The ulcer closure was achieved in 76 eyes (96.2%). The measures of BCVA, VAS and OSDI improved (p<0.001), and IOP remained unchanged ( p=0.665). No adverse events were recorded during the treatment.

Conclusions:

The use of RGTA and PRGF in non-infectious ulcers was effective and safe, and it could be a therapeutic alternative for this type of corneal diseases.

Financial Disclosure:

None